ERBB2 and cancer: Notably, Meng and coworkers demonstrated in 24 patients with HER2-negative primary tumors that nearly 40% acquired a HER2 gene amplification in CTCs during cancer progression; they first obtained proof of concept that patients treated with a Herceptin-containing therapy had a partial or complete response [197].